{"filings":[{"id":1303916,"accession_number":"0001104659-26-078251","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2026-06-26T20:06:26+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix increases ATM offering capacity by $2.5M to raise additional capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to increase aggregate offering under Sales Agreement with Rodman & Renshaw by $2.5M.","Previously sold ~$6.234M of common stock under prior prospectus supplements covering up to $6.406M.","Total maximum offering amount under the ATM facility now $8.906M ($6.406M + $2.5M).","Shares sold at market prices; proceeds used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027327,"accession_number":"0001104659-26-073430","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2026-06-12T20:05:59+00:00","items":["3.01","5.02","8.01","9.01"],"status":"ready","headline":"Soligenix terminates HyBryte program after Phase 3 futility; receives Nasdaq bid price deficiency notice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice for non-compliance with $1.00 minimum bid price; 180 days until Dec 7, 2026 to regain compliance.","Board terminated HyBryte (synthetic hypericin) development program after DMC recommended halt for futility.","Expected wind-down charges of approximately $70,000 from closing FLASH2 trial.","Consulting CMO Richard Straube stepped down; duties transitioned to Medical Director Christopher Pullion.","Company will evaluate strategic alternatives including M&A and advancing dusquetide (SGX945) for Behçet's Disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":724356,"accession_number":"0001104659-26-067649","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2026-05-28T21:21:17+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix increases at-market offering by $2.96M, total now up to $6.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on May 28, 2026, increasing shares issuable under Sales Agreement with Rodman & Renshaw by $2,956,000.","Prior sales under the agreement totaled approximately $3,445,000; combined maximum now $6,401,000.","Common stock (SNGX) offered on Nasdaq; legal opinion from Duane Morris LLP filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99009,"accession_number":"0001104659-26-049787","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix Phase 3 FLASH2 trial of HyBryte for CTCL halted for futility","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Data Monitoring Committee interim efficacy analysis recommended halt; HyBryte failed to show benefit at 18 weeks.","Company reports ~$5.9M cash; evaluating strategic options including M&A or advancing dusquetide for Behçet's Disease.","HyBryte previously showed statistically significant lesion reduction in Phase 3 FLASH study at 6 weeks, but not replicated in FLASH2.","Soligenix plans further data analysis to identify patient subsets; will discuss with FDA and EMA if warranted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114786,"accession_number":"0001104659-26-014267","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix provides pipeline update; FLASH 2 interim analysis in 2Q, cash through 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["66 patients enrolled in confirmatory Phase 3 FLASH 2 trial for HyBryte in CTCL as of Feb 10; interim analysis expected 2Q 2026.","Blinded aggregate response rate in FLASH 2 remains higher than estimated rate used to design study, increasing confidence.","Investigator-initiated study: 75% of patients achieved treatment success, 3 complete responses with HyBryte at 18 weeks.","Cash ~$10.5M as of Sep 30, 2025, plus ~$500k from NJ NOL program; runway through 2026.","Positive Phase 2a results for SGX945 (Behçet’s) and SGX302 (psoriasis); Phase 2b design underway in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114785,"accession_number":"0001104659-26-006233","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix enters ATM equity facility with Rodman & Renshaw for up to $3.45M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $3,450,000 of common stock may be sold at market prices through Rodman & Renshaw as sales agent.","Commission of 3.0% of gross proceeds; facility expires December 15, 2026.","Company can sell shares at its discretion; no minimum obligation to sell.","Sales will be made via an at-the-market offering under existing shelf registration statement (File No. 333-274265)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131165,"accession_number":"0001104659-25-113645","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Soligenix regains Nasdaq minimum stockholders' equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Nov 18, 2025 confirming compliance with minimum $2.5M stockholders' equity requirement.","Stockholders' equity was $7,597,976 as of Sept 30, 2025, well above the $2.5M threshold.","Prior deficiency notice was received on Aug 15, 2025; now the matter is closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147743,"accession_number":"0001104659-25-094507","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Soligenix closes $7.5M public offering; cash runway extended through 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$7.5M from sale of 5,555,560 units at $1.35/unit, each consisting of one share (or pre-funded warrant) and one warrant.","Warrants exercisable at $1.35 per share for five years from issuance; 1,162,064 existing warrants amended to same terms.","Cash runway now extends through end of 2026 to fund key clinical/commercial inflection points.","Net proceeds to fund R&D, commercialization, working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147742,"accession_number":"0001558370-25-011625","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Soligenix orphan drug designation for SGX945 in Behçet's Disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA orphan drug designation for dusquetide (SGX945) in Behçet's Disease based on Phase 2a results showing biological efficacy and safety.","Designation provides 7 years U.S. market exclusivity upon FDA approval, plus NDA fee waiver, tax credits, and clinical trial grants.","Behçet's Disease affects up to 18,000 in the U.S. and 1 million worldwide; current treatments have significant unmet need.","CEO notes Phase 2a study demonstrated clinically meaningful improvements in oral aphthous ulcers in Behçet's patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147741,"accession_number":"0001558370-25-011619","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Soligenix receives Nasdaq deficiency notice for stockholders' equity below $2.5M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $1,828,951 as of June 30, 2025, below Nasdaq's $2.5M minimum.","July 1 ATM sale raised ~$1.44M gross, but company still fails alternative listing standards.","Must submit compliance plan by Sept 29, 2025; if accepted, Nasdaq may extend up to 180 days.","Failure to regain compliance could lead to delisting; company may appeal to Nasdaq panel.","Common stock continues trading on Nasdaq Capital Market under SNGX pending plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147740,"accession_number":"0001104659-25-072708","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix SGX945 Phase 2a: 40% improvement in Behçet's ulcers, matching Otezla's 37%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SGX945 achieved 40% improvement vs placebo on primary endpoint at Week 4; apremilast (Otezla) had 37% improvement.","7 of 8 patients reported benefit; 1 patient's skin ulcer resolved; no treatment-related adverse events.","Improvement sustained at Week 8 (32%) despite stopping treatment at Week 4; Otezla continuous dosing had 41%.","Company plans reformulation for home subcutaneous injection and a placebo-controlled Phase 2 study.","Behçet's Disease affects ~18,000 in US; SGX945 well-tolerated with no GI side effects vs Otezla."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166429,"accession_number":"0001558370-25-008772","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Soligenix shareholders approve 2025 Equity Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan approved with 215,332 for, 91,937 against, 57,226 abstain; 1,168,832 broker non-votes.","Authorizes up to 6 million shares plus annual evergreen increase starting January 1, 2026.","Five directors elected: Schaber (330,950), Lapointe (332,492), Parks (331,054), Rubin (331,046), Zeldis (329,054).","Non-binding advisory vote on exec compensation passed: 303,633 for, 53,830 against.","Ratification of Cherry Bekaert LLP as auditor for FY2025 approved: 1,476,465 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183866,"accession_number":"0001558370-25-003987","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Soligenix amends bylaws to reduce stockholder meeting quorum to one-third from majority","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment effective March 25, 2025 reducing quorum from majority to one-third of voting power.","Company cited prior difficulties achieving quorum due to dispersed stockholder base and brokerage policy changes.","Amendment aims to avoid costly adjournments, increased proxy solicitation expenses, and management distraction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183865,"accession_number":"0001558370-25-000726","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Soligenix repays $10M Pontifax loan early, terminates Loan and Security Agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid all outstanding obligations under the December 2020 Loan Agreement with Pontifax Medison Finance.","No prepayment penalty incurred; all related liens and security interests released.","Loan was originally $10 million, originated on December 15, 2020.","Shlomo Karako, Partner of the Lenders, praised positive collaboration and professionalism.","Company and subsidiaries terminated the Loan Agreement effective February 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200464,"accession_number":"0001558370-24-013257","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Soligenix amends loan deal with Pontifax; conversion price cut to $3.81/$4.23","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Conversion price reduced to $3.81 for first 501,648 shares issued after Oct 7, 2024, then $4.23 for subsequent shares.","Amendment allows Soligenix to satisfy remaining loan balance with stock instead of cash, extending cash runway.","Lenders agreed to lock-up in future offerings and capped aggregate stock ownership at 19.99% of outstanding shares.","All other terms of the December 2020 Loan and Security Agreement remain unchanged; effective October 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216495,"accession_number":"0001558370-24-012345","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix enters ATM equity sales agreement for up to $5.8M with AGP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with A.G.P./Alliance Global Partners allows sale of up to $5.8M in common stock at market prices from time to time.","Company will pay AGP a fixed commission rate of up to 3.0% of gross proceeds from sales under the agreement.","Sales may occur through The Nasdaq Capital Market until earliest of December 15, 2026, sale of all shares, or termination.","Shares issued under effective shelf registration statement declared Dec. 15, 2023; prospectus supplement filed Aug. 16, 2024.","Company has no obligation to sell any shares and may suspend or terminate the agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216494,"accession_number":"0001558370-24-010107","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Soligenix regains Nasdaq compliance after reverse stock split, delisting threat resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 24, 2024 confirming regained compliance with Minimum Bid Price Rule.","Effected a 1-for-16 reverse stock split on June 5, 2024 to boost share price above $1.00.","Previously disclosed non-compliance as of June 23, 2023; hearings panel closed matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216493,"accession_number":"0001558370-24-009712","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Soligenix induces warrant exercise for up to $4.2M, issues new warrants at 150% coverage","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to 703,125 existing warrants exercised at $6.00/share; gross proceeds up to ~$4.2M.","For each exercised warrant, company issues new warrant to purchase 150% of shares, exercisable at $6.00, 5-year term.","New warrants unregistered; company to file S-1 resale registration by July 25, 2024.","A.G.P. receives 6% fee of gross proceeds; net proceeds for clinical development and working capital.","Exhibit warns of potential Nasdaq delisting risk if compliance not regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236122,"accession_number":"0001558370-24-008803","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","7.01","9.01"],"status":"ready","headline":"Soligenix to effect 1-for-16 reverse stock split effective June 5, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-16 ratio; effective 4:00 p.m. EST June 5, 2024.","Outstanding shares to reduce from 15,799,837 to ~987,490 (fractional shares rounded up).","Common stock begins trading on split-adjusted basis June 6, 2024 under ticker SNGX; new CUSIP 834223 604.","Stockholders approved reverse split at annual meeting; board set ratio at 1-for-16.","Proportionate adjustments to equity awards and warrants exercise prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236121,"accession_number":"0001558370-24-008642","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Soligenix adjourns 2024 annual meeting due to insufficient quorum; reconvenes May 30","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Only ~48% of outstanding shares were represented at May 23 meeting, below required majority.","Meeting adjourned to May 30, 2024 at 9:00 a.m. ET; will be held virtually.","Record date for voting remains April 10, 2024.","Company urges stockholders to vote via Internet, phone, or by contacting proxy solicitor Alliance Advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236120,"accession_number":"0001558370-24-008421","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix confirms compliance with Nasdaq $2.5M equity requirement after debt conversion and public offering","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Converted $154,840 of debt into equity on April 15, 2024.","Closed a $4.75 million public offering on April 22, 2024.","Company now believes it meets Nasdaq’s $2.5 million shareholders’ equity minimum.","These events were previously reported in the Q1 2024 10-Q filed May 10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236119,"accession_number":"0001558370-24-005411","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Soligenix prices $4.75M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.75M from unit offering: one share (or pre-funded warrant) and one common warrant per unit.","Units priced at $0.40; warrants exercisable at $0.40 per share with a five-year term.","Offering comprises up to 11.875M shares/common equivalents and 11.875M warrants; 8.6M pre-funded warrants included.","Net proceeds to fund R&D, commercialization activities, and general corporate and working capital purposes.","Closing expected on or about April 22, 2024; A.G.P./Alliance Global Partners acting as sole placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236118,"accession_number":"0001558370-24-004663","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix gets EMA agreement on confirmatory Phase 3 design for HyBryte in CTCL","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA agreed on key design for FLASH2: double-blind, placebo-controlled, 18-week continuous treatment.","Study to enroll ~80 early-stage CTCL patients in US and Europe; enrollment targeted by end of 2024.","Primary endpoint: ≥50% reduction in mCAILS score at Week 18; top-line results expected H2 2026.","FLASH2 replicates first Phase 3 design but extends continuous treatment without breaks.","Discussions with FDA on US development path remain ongoing; company prioritizes EMA pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271286,"accession_number":"0001558370-23-019993","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Soligenix receives Nasdaq delisting notice; common stock may be suspended","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Soligenix on Dec 21, 2023, of failure to meet $1.00 minimum bid price rule.","Company ineligible for second 180-day cure period due to stockholders' equity of $4.22M (below $5M minimum).","Intends to request a hearing by Dec 28, 2023, to stay suspension pending panel decision.","Hearing expected within 45 days; company will present plan to regain compliance.","No immediate impact on listing; shares continue trading on Nasdaq under symbol SNGX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271285,"accession_number":"0001558370-23-019838","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Soligenix reconvenes annual meeting; elects all five director nominees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees were elected: Schaber, Lapointe, Parks, Rubin, Zeldis.","Advisory vote on executive compensation passed with 2,315,274 For vs. 707,529 Against.","Ratification of Cherry Bekaert LLP as auditor approved with 4,439,358 For.","Meeting required multiple adjournments from Sept 21, Oct 18, Nov 16 until quorum achieved.","Broker non-votes totaled 1,602,901 on director election and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271284,"accession_number":"0001558370-23-019193","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Soligenix adjourns 2023 annual meeting again; only 46.46% quorum achieved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting reconvened on Nov 16, 2023 failed to achieve quorum; adjourned to Dec 15, 2023.","Proxies submitted represented only 46.46% of outstanding shares; majority required for quorum.","Record date remains July 24, 2023; shareholders urged to vote by internet or phone.","No business was transacted at the meeting; company continues soliciting votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271283,"accession_number":"0001558370-23-016573","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Soligenix adjourns annual meeting due to insufficient quorum; reconvened Nov 16","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting reconvened Oct 18 adjourned for lack of quorum; no business transacted.","Only 39.3% of outstanding shares were represented as of adjournment.","Meeting rescheduled to Nov 16, 2023 at 9:00 a.m. ET, held virtually.","Record date for voting remains July 24, 2023; stockholders urged to vote.","Proxies solicited for proposals in proxy statement filed Aug 7, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288147,"accession_number":"0001558370-23-015942","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Soligenix annual meeting adjourned due to insufficient quorum; reconvened Oct 18","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Only 8.3% of shares voted as of Sept 21, 2023; quorum required a majority.","Meeting adjourned to Oct 18, 2023 at 9:00 a.m. ET, held virtually at www.virtualshareholdermeeting.com/sngx2023.","New proposal added: ratification of Cherry Bekaert LLP as independent auditor for FY2023.","Record date for voting remains July 24, 2023; stockholders urged to vote via www.proxyvote.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288146,"accession_number":"0001558370-23-015812","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-09-15T23:59:59+00:00","items":["4.01","8.01","9.01"],"status":"ready","headline":"Soligenix dismisses auditor EisnerAmper, engages Cherry Bekaert; notes material weakness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed EisnerAmper and engaged Cherry Bekaert as new independent auditor for FY 2023.","No disagreements on accounting matters in prior two fiscal years; 2022 report included going concern qualification.","Company discloses material weakness in internal control over financial reporting related to complex financial instruments.","Proposal to ratify EisnerAmper appointment at Sept 21 annual meeting withdrawn; Cherry Bekaert to be recommended in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288145,"accession_number":"0001558370-23-011750","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Soligenix director Timothy R. Coté resigns for personal reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy R. Coté resigned from the Board of Directors effective July 7, 2023.","Resignation was for personal reasons; no disagreements with company operations or policies.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308587,"accession_number":"0001558370-23-011374","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Soligenix receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 23, 2023 for failing $1.00 minimum bid price for 30 consecutive business days.","Has until December 20, 2023 to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not compliant, may qualify for second 180-day period if meets other listing standards and intends reverse split.","Trading continues under symbol SNGX on Nasdaq Capital Market with no immediate delisting effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308586,"accession_number":"0001558370-23-010537","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Soligenix regains Nasdaq compliance; Panel Monitor imposed for one year","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on May 23, 2023 confirming regained compliance with Shareholders' Equity Requirement.","Compliance achieved as of May 9, 2023 through recent capital raising activities.","Panel Monitor imposed for one year; must notify Nasdaq if bid price falls below $1.00 or violates other listing rules.","Previously satisfied Minimum Bid Price Requirement on Feb 24, 2023 after ten consecutive sessions above $1.00.","Nasdaq delisting matter closed; common stock (SNGX) continues trading on The Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308585,"accession_number":"0001558370-23-008833","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Soligenix closes $8.5M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 6,538,500 units (common stock or pre-funded warrants plus common warrants) at $1.30/unit.","Gross proceeds of ~$8.5M before fees and expenses; warrants exercisable at $1.50 for 5 years.","Closed May 9, 2023; A.G.P./Alliance Global Partners as sole placement agent.","Proceeds to fund R&D, commercialization, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308584,"accession_number":"0001558370-23-007875","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Soligenix appoints Timothy Coté to board, expands size to six","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 5 to 6; Timothy R. Coté, M.D. appointed as director, term expiring at 2023 annual meeting.","Dr. Coté granted fully-vested non-qualified stock option for 15,000 shares at $1.42 per share, plus $35,000 annual cash.","Former FDA OOPD director, implementing Orphan Drug Act; founded Coté Orphan sold to IQVIA for $20M.","Also CEO of Silk Road Therapeutics; Soligenix recently acquired exclusive option to its PTX topical for Behçet's Disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308583,"accession_number":"0001558370-23-007396","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix obtains exclusive option for Phase 2/3-ready topical Pentoxifylline in Behçet's Disease","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive option agreement with Silk Road Therapeutics to acquire topical Pentoxifylline for mucocutaneous ulcers in Behçet's Disease.","BD affects ~18,000 US, 80,000 EU patients; orphan disease with no cure, current treatments limited.","Phase 2 trial showed 83% of PTX patients had ulcer shrinkage by Day 2 vs 19% colchicine (p<0.0001).","By Day 4, 72% on PTX had undetectable ulcer vs 29% colchicine; no serious adverse events.","Program is Phase 2/3-ready; Soligenix plans FDA discussions on trial design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308582,"accession_number":"0001558370-23-006237","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Soligenix amends loan with Pontifax; repays $5M; reduces minimum cash covenant to $1.5M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $5M of $8M loan principal, leaving $3M outstanding; prepayment premium eliminated.","Minimum cash covenant reduced from $4.5M to $1.5M; falls to $0 if $10M raised by Dec 31, 2023.","Conversion price set at 90% of prior day's close for first 588,599 shares; $1.70 thereafter.","FDA refusal to file HyBryte NDA triggered an Event of Default, waived until Dec 31, 2023 if $5.6M raised.","Interest-only period extended to Dec 31, 2023 if $5.6M raised; to June 30, 2024 if $10M raised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308581,"accession_number":"0001558370-23-005925","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix says FDA requires second Phase 3 study for HyBryte NDA after Type A meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA refused to file NDA for HyBryte (CTCL); requires positive results from a second clinical study.","Type A Meeting held April 14, 2023; FDA open to protocol discussions for the additional study.","Company disappointed but will collaborate with FDA; evaluating feasibility of conducting the trial.","Phase 3 FLASH study was the largest double-blind, placebo-controlled CTCL trial; met primary endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308580,"accession_number":"0001558370-23-005653","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Soligenix gets Nasdaq extension to May 15, 2023 for equity listing compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq extended the deadline to regain Shareholders' Equity Requirement compliance from March 31, 2023 to May 15, 2023.","Company had previously satisfied the Minimum Bid Price Requirement on February 24, 2023.","No assurance that Soligenix will meet the equity requirement by the new deadline or remain listed.","Failure to comply could lead to delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327382,"accession_number":"0001558370-23-002040","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq grants Soligenix continued listing subject to stockholders' equity compliance by March 31, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted continued listing conditional on meeting minimum bid price by Feb 24 and stockholders' equity by March 31, 2023.","Soligenix satisfied the bid price condition as of Feb 24, 2023 (closing bid >= $1.00 for 10 consecutive sessions).","Company must demonstrate compliance with $2.5M stockholders' equity requirement by March 31, 2023; no assurance of success.","Original delisting notice (Dec 20, 2022) cited failure of both minimum bid price and stockholders' equity rules.","Hearing was held Feb 2, 2023; Panel granted extension with conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327381,"accession_number":"0001558370-23-001226","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix receives FDA Refusal to File for HyBryte NDA in CTCL","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued Refusal to File (RTF) letter for HyBryte NDA for early-stage cutaneous T-cell lymphoma.","NDA submitted Dec 14, 2022 deemed not sufficiently complete for substantive review.","Soligenix plans to request a Type A meeting to clarify issues and seek guidance for resubmission.","Cutaneous T-cell lymphoma is a rare cancer affecting over 25,000 patients in the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327380,"accession_number":"0001558370-23-001056","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","7.01","9.01"],"status":"ready","headline":"Soligenix to effect 1-for-15 reverse stock split, effective Feb 9, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split (range 1:2 to 1:20) at Feb 8 special meeting; board set ratio at 1:15.","Outstanding shares reduce from ~43.3M to ~2.9M; fractional shares rounded up; par value unchanged.","Trading symbol SNGX unchanged; split-adjusted trading begins Feb 10 on Nasdaq; new CUSIP 834223505.","Proportional adjustments made to exercise prices and shares issuable upon exercise of options and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327379,"accession_number":"0001558370-23-000194","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Soligenix releases video discussing reverse stock split and 2023 milestones","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Special meeting on Feb 8, 2023 to vote on reverse stock split at ratio of 1-for-2 to 1-for-20.","Board will determine final ratio and announce publicly.","CEO discusses rationale for reverse split and importance of stockholder approval.","Video also summarizes key potential 2023 milestones for the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345094,"accession_number":"0001558370-22-018987","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2022-12-27T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Soligenix declares Series D Preferred Stock dividend to enable reverse stock split vote for Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date Jan 3, 2023; distribution Jan 4, 2023; each common share gets 1/1000th of Series D.","Series D carries 1,000 votes per share on reverse stock split proposal only.","Company received Nasdaq deficiency letter for minimum bid price non-compliance.","Reverse stock split needed to maintain listing; stock price did not respond as hoped despite NDA submission.","Unredeemed Series D shares redeemed automatically upon stockholder approval of reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345093,"accession_number":"0001558370-22-018968","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Soligenix receives Nasdaq delisting notice for failure to meet $1.00 bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Soligenix on Dec 20, 2022 that it failed to regain compliance with the Minimum Bid Price Rule by the Dec 19, 2022 deadline.","Company will request a hearing by Dec 27 to stay trading suspension; hearing expected within 45 days.","Also notified Nov 16, 2022 for non-compliance with $2.5M stockholders' equity requirement.","Board proposes reverse stock split (1-for-2 to 1-for-20) to regain compliance; preliminary proxy filed Dec 23.","Stock continues trading under SNGX while hearing is pending; no guarantee of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345092,"accession_number":"0001558370-22-018776","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix opens enrollment in Phase 2a trial of SGX302 for mild-to-moderate psoriasis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a study (HPN-PSR-01) initiating enrollment of up to 42 patients with mild-to-moderate psoriasis.","Part A open-label (5-10 patients) followed by Part B double-blind 1:1 active vs. placebo for 18 weeks treatment plus 4-week follow-up.","SGX302 (synthetic hypericin) activated by visible light; efficacy endpoints include lesion clearance and quality of life.","Psoriasis affects ~7.5M people in U.S. and 60-125M worldwide; Soligenix estimates >$1B global market for SGX302.","SGX302 also under NDA review for cutaneous T-cell lymphoma (Phase 3 FLASH study)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345091,"accession_number":"0001558370-22-018677","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2022-12-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix submits NDA to FDA for HyBryte in cutaneous T-cell lymphoma; targets H2 2023 approval","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA submitted for HyBryte (synthetic hypericin) to treat early stage CTCL, a rare cancer affecting >25,000 US patients.","NDA has FDA orphan drug and fast track designations; company anticipates potential approval in H2 2023.","Company estimates worldwide market for HyBryte in CTCL at over $250 million.","US launch targeted for Q1 2024, contingent upon FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345090,"accession_number":"0001558370-22-018089","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["3.01","5.07","9.01"],"status":"ready","headline":"Soligenix receives Nasdaq non-compliance notice for equity deficiency; share increase vote fails","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $1,032,002 reported for Q3 2022 falls below Nasdaq's $2.5M minimum.","Company has 45 days to submit a compliance plan; possible extension of up to 180 days.","Proposal to increase authorized shares from 75M to 125M failed; 19.25M votes for (80% cast) but not majority of outstanding.","Management evaluating options to regain compliance; no assurance of success.","Common stock continues trading on Nasdaq under SNGX pending compliance plan review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345089,"accession_number":"0001558370-22-015497","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Soligenix invited by BARDA to submit $25M contract proposal for Ebola/Marburg vaccines","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BARDA invites Soligenix to submit full contract proposal for SuVax and MarVax vaccines.","Program valued up to $25M over 5 years for SuVax Phase 1 studies, with options for MarVax.","SuVax demonstrated 100% protection in non-human primate model with 3-dose series.","No protective vaccines currently available for Sudan ebolavirus or Marburg marburgvirus.","Contract award not guaranteed; requires favorable technical review and negotiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345088,"accession_number":"0001558370-22-015319","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2022-10-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Soligenix forms Psoriasis Medical Advisory Board; Phase 2a study starts December 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Formed Medical Advisory Board (MAB) for SGX302 (synthetic hypericin) in mild-to-moderate psoriasis.","Phase 2a clinical study anticipated to begin in December 2022; FDA previously cleared IND and protocol.","MAB chaired by Neal Bhatia, MD (Therapeutics Clinical Research, San Diego).","Previous positive Phase 3 trial of HyBryte (same synthetic hypericin) in CTCL supports psoriasis program.","Psoriasis affects >7.5 million patients in the U.S.; MAB includes four board-certified dermatologists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345087,"accession_number":"0001558370-22-015097","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2022-10-20T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Soligenix adjourns annual meeting to Nov 17 for vote on share increase from 75M to 125M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Meeting reconvenes Nov 17, 2022 at 9:00 a.m. ET solely for Proposal 2 (authorized share increase).","Proposal 2 support exceeds 80% of votes cast but requires >50% of outstanding shares to pass.","Record date remains July 25, 2022; previously submitted proxies count unless revoked.","Company states share increase critical for HyBryte™ NDA filing and commercial launch activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-10-20T23:59:59+00:00|345087"}